Routinely offer MenB jabs to prevent gonorrhoea, UK vaccine committee recommends

The Joint Committee on Vaccination and Immunisation (JCVI) has advised the UK government that meningococcal B (MenB) vaccines should be routinely offered to prevent gonorrhoea by targeting the people at greatest risk.1Evidence indicates that, even with a modest vaccine effectiveness against gonorrhoea of 32.7-42.0%, rolling out the 4CMenB vaccine to groups with the highest risk could prevent many cases, said the committee. Because infection with the Neisseria gonorrhoeae bacterium does not protect against future infection, many people are commonly reinfected.Andrew Pollard, JCVI chair, said that a programme to target high risk people with the MenB vaccine would be a “world first” and should “significantly help to reduce levels of gonorrhoea, which are currently at a record high.”Earlier this year the UK Health Security Agency (UKHSA) warned that gonorrhoea diagnoses had increased by 50% from 54 961 in 2021 to 82 592 in 2022—the highest number since records began in 1918….
Read Original Article: Routinely offer MenB jabs to prevent gonorrhoea, UK vaccine committee recommends »